Ascendis Pharma A/S

120.57-1.38-1.13%Vol 109.59K1Y Perf -6.49%
Apr 19th, 2021 14:48 DELAYED
BID120.40 ASK120.79
Open121.46 Previous Close121.95
Pre-Market- After-Market-
 - -%  - -
Target Price
194.60 
Analyst Rating
Strong Buy 1.07
Potential %
61.49 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.86
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     63.89
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap6.48B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
2.25 
Earnings Date
18th May 2021

Today's Price Range

119.11122.17

52W Range

119.11183.98

5 Year PE Ratio Range

-17.50-14.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.91%
1 Month
-15.31%
3 Months
-22.78%
6 Months
-23.05%
1 Year
-6.49%
3 Years
83.60%
5 Years
595.27%
10 Years
-

TickerPriceChg.Chg.%
ASND120.57-1.3800-1.13
AAPL134.450.29000.22
GOOG2 300.692.93000.13
MSFT258.85-1.8900-0.72
XOM56.28-0.3800-0.67
WFC44.230.39000.89
JNJ162.790.55000.34
FB301.87-4.3100-1.41
GE13.410.02000.15
JPM153.25-0.0500-0.03
Financial StrengthValueIndustryS&P 500US Markets
13.80
14.00
0.09
0.11
-217.50
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-3 583.10
-3 488.60
-3 703.00
-
RevenueValueIndustryS&P 500US Markets
5.98M
0.11
75.38
5.65
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.84-3.15-71.20
Q03 2020-1.88-2.70-43.62
Q02 2020-1.66-2.17-30.72
Q01 2020-1.43-1.46-2.10
Q04 2019-1.27-1.88-48.03
Q03 2019-1.37-0.5956.93
Q02 2019-1.32-1.40-6.06
Q01 2019-0.97-1.41-45.36
Earnings Per EndEstimateRevision %Trend
3/2021 QR-2.00-1.52Negative
6/2021 QR-2.37-11.27Negative
12/2021 FY-8.92-16.75Negative
12/2022 FY-7.48-18.54Negative
Next Report Date18th May 2021
Estimated EPS Next Report-2.00
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume109.59K
Shares Outstanding53.75M
Trades Count2.37K
Dollar Volume49.77M
Avg. Volume205.95K
Avg. Weekly Volume200.20K
Avg. Monthly Volume244.13K
Avg. Quarterly Volume218.01K

Ascendis Pharma A/S (NASDAQ: ASND) stock closed at 121.95 per share at the end of the most recent trading day (a -1.8% change compared to the prior day closing price) with a volume of 307.22K shares and market capitalization of 6.48B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 330 people. Ascendis Pharma A/S CEO is Jan Moller Mikkelsen.

The one-year performance of Ascendis Pharma A/S stock is -6.49%, while year-to-date (YTD) performance is -26.88%. ASND stock has a five-year performance of 595.27%. Its 52-week range is between 119.11 and 183.98, which gives ASND stock a 52-week price range ratio of 2.25%

Ascendis Pharma A/S currently has a PE ratio of -13.20, a price-to-book (PB) ratio of 6.99, a price-to-sale (PS) ratio of 1 109.12, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -50.58%, a ROC of -35.78% and a ROE of -58.36%. The company’s profit margin is -%, its EBITDA margin is -3 488.60%, and its revenue ttm is $5.98 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from Ascendis Pharma A/S, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-2.00 for the next earnings report. Ascendis Pharma A/S’s next earnings report date is 18th May 2021.

The consensus rating of Wall Street analysts for Ascendis Pharma A/S is Strong Buy (1.07), with a target price of $194.6, which is +61.49% compared to the current price. The earnings rating for Ascendis Pharma A/S stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ascendis Pharma A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ascendis Pharma A/S has a Sell technical analysis rating based on Technical Indicators (ADX : 8.92, ATR14 : 6.68, CCI20 : -117.86, Chaikin Money Flow : -0.18, MACD : -8.80, Money Flow Index : 24.03, ROC : -5.21, RSI : 37.85, STOCH (14,3) : 7.10, STOCH RSI : 0.43, UO : 33.14, Williams %R : -92.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ascendis Pharma A/S in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
7 (87.50 %)
7 (87.50 %)
Moderate Buy
1 (14.29 %)
1 (12.50 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.07
Strong Buy
1.06
Strong Buy
1.06

Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others.

CEO: Jan Moller Mikkelsen

Telephone: +45 70222244

Address: Tuborg Boulevard 12, Hellerup DK-2900, , DK

Number of employees: 330

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

59%41%

Bearish Bullish

69%31%

News

Stocktwits